Sign in
CompletedPhase 1

Cefiderocol PK in Patients on ECMO

Key facts

Who runs it
Joseph L. Kuti, PharmD
Where
Hartford and New York, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
5 people enrolled
Started
16 Jul 2021
Ended
1 Sept 2024
Type of study
Interventional
Treatments tested
  • Cefiderocol
Record updated
16 December 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • 18 years of age or older
  • On support with veno-venous- or veno-arterial-ECMO

Who cannot take part

  • Receiving Cefiderocol to treat documented or suspected infection within 72 hours of screening, or expected to receive Cefiderocol during the study intervention phase
  • Severe renal dysfunction defined as a CrCL < 15 mL/min (as calculated by the Cockcroft Gault equation using actual body weight) or requirement for continuous renal replacement therapy or hemodialysis
  • History of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibiotic (a history of mild rash to a cephalosporin followed by uneventful re-exposure is not a contraindication)
  • Any rapidly progressing disease or immediately life-threatening illness (defined as imminent death within 48 hours in the opinion of the investigator)
  • Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of study data
  • A hemoglobin less than 7.2 gm/dl at baseline
  • Acute liver injury, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times the upper limit of normal, or AST or ALT > 3 times the upper limit of normal with an associated total bilirubin > 2 times upper limit of normal
  • Females who are pregnant or breast-feeding

Where in United States

  • Hartford HospitalHartford, United States
  • Columbia University/New York Presbyterian HospitalNew York, United States

About the trial

What the trial wants to find out

Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and reinfused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, Cefiderocol, in critically ill patient receiving ECMO.

The group in the trial

  • CefiderocolTreatment being tested

    Participants will receive four to six doses of Cefiderocol as per current prescribing information based on calculated creatinine clearance.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ex Vivo Sequestration and Pharmacokinetics of Cefiderocol in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
Record updated
16 December 2024